# Combined Antiplatelet Strategy in Acute Ischemic Stroke Following Thrombectomy and/or Intravenous Thrombolysis (CoPRIME)

Study · id `cardio:ct-nct07844603` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07844603](<https://clinicaltrials.gov/study/NCT07844603>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07844603

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 300 participants.

## Technical summary

Registry record NCT07844603. Randomized; no masking; primary purpose treatment. Start 2027-01-01 (anticipated); primary completion 2030-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 300 participants (planned count; ClinicalTrials.gov record NCT07844603, source copy `cardio:ctgov-nct07844603-2026-11-13`, retrieved 2026-11-18)
- Planned start: 2027-01-01 (anticipated) (ClinicalTrials.gov record NCT07844603, source copy `cardio:ctgov-nct07844603-2026-11-13`, retrieved 2026-11-18)
- Primary completion: 2030-12-31 (anticipated) (ClinicalTrials.gov record NCT07844603, source copy `cardio:ctgov-nct07844603-2026-11-13`, retrieved 2026-11-18)
- Completion: 2030-12-31 (anticipated) (ClinicalTrials.gov record NCT07844603, source copy `cardio:ctgov-nct07844603-2026-11-13`, retrieved 2026-11-18)
- Countries: Canada (ClinicalTrials.gov record NCT07844603, source copy `cardio:ctgov-nct07844603-2026-11-13`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07844603-2026-11-13`, retrieved 2026-11-18)

## The registry's words

- Brief title: Combined Antiplatelet Strategy in Acute Ischemic Stroke Following Thrombectomy and/or Intravenous Thrombolysis (CoPRIME)
- Acronym: CoPRIME
- Condition: Acute Ischemic Stroke
- Intervention (Drug): Aspirin + Clopidogrel
- Intervention (Drug): Aspirin
- Intervention (Drug): Aspirin + Ticagrelor
- Lead sponsor: University of Alberta
- Lead sponsor class: OTHER
- Collaborator: University of Calgary
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry intervention name matches this record: Aspirin (`core:aspirin`)
- Registry lists this organization as the lead sponsor: University of Alberta (`cardio:org-university-of-alberta`)
- Registry lists this organization as a collaborator: University of Calgary (`cardio:org-university-of-calgary`)

## Provenance

Content hash: a8740235fefead5522fec6896006e533055b8608207560ba0b89f29d5bc6f489
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
